FLX Bio, Inc. announced that it has appointed Paul Kassner as Vice President, Quantitative Biology and David Wustrow as Vice President, Drug Discovery. They join an experienced management team including Jordan Fridman Chief Scientific Officer; William Ho Chief Medical Officer; and Brian Wong, President and CEO. Dr. Kassner joined FLX Bio after 18 years of building and leading high performance technical groups in various biopharmaceutical organizations. Most recently, he was Director of Research and Head of the Genome Analysis Unit at Amgen, Inc. Dr. Wustrow has more than 25 years of experience in pharmaceutical research and development, including
medicinal chemistry, drug metabolism and pharmacokinetics, preclinical development, and drug product manufacturing. Prior to FLX Bio Dr. Wustrow held the position of Vice President, Chemical and Pharmaceutical Sciences at Cleave Biosciences, where he led chemistry efforts directed towards the discovery and development of drug products for solid and hematologic malignancies.